难治性高血压的研究进展

廖 　莉
湖南省沅江市人民医院心内科

摘要


难治性高血压（refractory hypertension，RfHT）是一种抗高血压治疗失败的极端表型，尽管使用了至少5种
抗高血压药物，包括长效利尿剂和醛固酮受体拮抗剂，但血压（blood pressure）水平仍不受控制。2012年提出RfHT
是顽固性高血压（resistant hypertension，RHT）的一个分支，但是目前国内RfHT和RHT两个概念在交叉使用。相
对于RHT患者，RfHT患者的预后更差，心血管和肾脏不良结局和死亡率的风险更高。因此，识别、诊断RfHT个
体、制定相应的干预措施非常重要。

关键词


难治性高血压；顽固性高血压；患病率；临床特征；预后

全文:

PDF


参考


[1]WHO. Global Health Observatory [Online]. https://

www.who.int/gho/ncd/risk_factors/ blood_ pressure_

prevalence /en/. Accessed April 11, 2019.

[2]蓝林飞，李宗祥，漆秦可，刘一平.运动对顽固

性高血压患者降压效果的Meta分析[J].福建体育科技，

2023，42（1）：37-44.

[3]Calhoun DA, Jones D, Textor S, Goff DC, Murphy

TP, Toto RD, White A, Cushman WC, White W, Sica D,

Ferdinand K, Giles TD, Falkner B, Carey RM; American

Heart Association Professional Education Committee.

Resistant hypertension: diagnosis, evaluation, and treatment:

a scientific statement from the American Heart Association

Professional Education Committee of the Council for

High Blood Pressure Research. Circulation. 2008 Jun

24;117(25):e510-26.

[4]Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia

LJ, Cartmill F, Zhang B, Cofield SS, Oparil S, Calhoun

DA. Refractory hypertension: definition, prevalence, and

patient characteristics. J Clin Hypertens (Greenwich). 2012

Jan;14(1):7-12.

[5]刘国树.顽固性高血压定义的演变[J].中国药物应

用与监测，2016，13（6）：329-332.

[6]朱瑶瑶，林忠伟.顽固性高血压的发病机制和治

疗进展[J].实用医学杂志，2020，36（12）：1689-1692.

[7]Buhnerkempe MG, Botchway A, Prakash V, AlAkchar M, Nolasco Morales CE, Calhoun DA, Flack JM.

Prevalence of refractory hypertension in the United States

from 1999 to 2014. J Hypertens. 2019 Sep;37(9):1797-1804.

[8]Dudenbostel T, Siddiqui M, Oparil S, Calhoun

DA. Refractory Hypertension: A Novel Phenotype of

Antihypertensive Treatment Failure. Hypertension. 2016

Jun;67(6):1085-92.

[9]Siddiqui M, Dudenbostel T, Calhoun DA. Resistant

and Refractory Hypertension: Antihypertensive Treatment

Resistance vs Treatment Failure. Can J Cardiol. 2016

May;32(5):603-6.

[10]Matanes F, Khan MB, Siddiqui M, Dudenbostel

T, Calhoun D, Oparil S. An Update on Refractory

Hypertension. Curr Hypertens Rep. 2022 Jul;24(7):225-234.

[11]Bacan G, Ribeiro-Silva A, Oliveira VAS, Cardoso

CRL, Salles GF. Refractory Hypertension: a Narrative

Systematic Review with Emphasis on Prognosis. Curr

Hypertens Rep. 2022 Apr;24(4):95-106.

[12]Calhoun DA, Booth JN 3rd, Oparil S, Irvin MR,

Shimbo D, Lackland DT, Howard G, Safford MM, Muntner

P. Refractory hypertension: determination of prevalence, risk

factors, and comorbidities in a large, population-based cohort.

Hypertension. 2014 Mar;63(3):451-8.

[13]Armario P, Calhoun DA, Oliveras A, Blanch P,

Vinyoles E, Banegas JR, Gorostidi M, Segura J, Ruilope

LM, Dudenbostel T, de la Sierra A. Prevalence and Clinical

Characteristics of Refractory Hypertension. J Am Heart

Assoc. 2017 Dec 7;6(12):e007365.

[14]Cao G, Chen C, Lin Q, Chen Y, Zhen Z, Zou

Y, Liu J, Wu M, Wang R, Liu M, Zhao C, Lu S, Ng MY,

Tse HF, Yiu KH. Prevalence, clinical characteristics and

echocardiography parameters of non-resistant, resistant and

refractory hypertension in Chinese. Postgrad Med. 2017

Mar;129(2):187-192.

[15]Sarfo FS, Akassi J, Adamu S, Obese V, Agbenorku

M, Ovbiagele B. Frequency and factors linked to refractory

hypertension among stroke survivors in Ghana. J Neurol Sci.

2020 Aug 15;415:116976.

[16]Navarro-Soriano C, Martínez-García MA,

Torres G, Barbé F, Caballero-Eraso C, Lloberes P,

Cambriles TD, Somoza M, Masa JF, González M, Mañas

E, de la Peña M, García-Río F, Montserrat JM, Muriel

A, Oscullo G, Olmos LF, García-Ortega A, Calhoun D,

Campos-Rodriguez F; Spanish Sleep Network. Factors

associated with the changes from a resistant to a refractory

phenotype in hypertensive patients: a Pragmatic Longitudinal

Study. Hypertens Res. 2019 Nov;42(11):1708-1715.

[17]Gaddam KK, Nishizaka MK, Pratt-Ubunama MN,

Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization

of resistant hypertension: association between resistant

hypertension, aldosterone, and persistent intravascular volume

expansion. Arch Intern Med. 2008 Jun 9;168(11):1159-64.

[18]Dudenbostel T, Acelajado MC, Pisoni R, Li

P, Oparil S, Calhoun DA. Refractory Hypertension:

Evidence of Heightened Sympathetic Activity as a Cause of

Antihypertensive Treatment Failure. Hypertension. 2015

Jul;66(1):126-33.

[19]Velasco A, Siddiqui M, Kreps E, Kolakalapudi P,

Dudenbostel T, Arora G, Judd EK, Prabhu SD, Lloyd SG,

Oparil S, Calhoun DA. Refractory Hypertension Is not

Attributable to Intravascular Fluid Retention as Determined

by Intracardiac Volumes. Hypertension. 2018 Aug;72(2):343-

349.

[20]Siddiqui M, Bhatt H, Judd EK, Oparil S, Calhoun

DA. Reserpine Substantially Lowers Blood Pressure in Patients

With Refractory Hypertension: A Proof-of-Concept Study.

Am J Hypertens. 2020 Aug 4;33(8):741-747.

[21]Krum H, Schlaich MP, Sobotka PA, Böhm

M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD.

Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity

HTN-1 study. Lancet. 2014 Feb 15;383(9917):622-9.

[22]Esler MD, Böhm M, Sievert H, Rump CL,

Schmieder RE, Krum H, Mahfoud F, Schlaich MP.

Catheter-based renal denervation for treatment of patients

with treatment-resistant hypertension: 36 month results from

the SYMPLICITY HTN-2 randomized clinical trial. Eur

Heart J. 2014 Jul;35(26):1752-9.

[23]Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino

R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita

M, Cohen SA, Oparil S, Rocha-Singh K, Townsend

RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A

controlled trial of renal denervation for resistant hypertension.

N Engl J Med. 2014 Apr 10;370(15):1393-401.

[24]Falkovskaya AY, Mordovin VF, Pekarskiy SE,

Manukyan MA, Ripp TM, Zyubanova IV, Lichikaki

VA, Sitkova ES, Gusakova AM, Baev AE. Refractory and

Resistant Hypertension in Patients with Type 2 Diabetes

Mellitus: Different Response to Renal Denervation.

Kardiologiia. 2021 Mar 9;61(2):54-61.

[25]Cardoso CRL, Salles GF. Refractory Hypertension

and Risks of Adverse Cardiovascular Events and Mortality in

Patients With Resistant Hypertension: A Prospective Cohort

Study. J Am Heart Assoc. 2020 Sep;9(17):e017634.

[26]Buhnerkempe MG, Prakash V, Botchway A,

Adekola B, Cohen JB, Rahman M, Weir MR, Ricardo

AC, Flack JM. Adverse Health Outcomes Associated With

Refractory and Treatment-Resistant Hypertension in the

Chronic Renal Insufficiency Cohort. Hypertension. 2021

Jan;77(1):72-81.


Refbacks

  • 当前没有refback。